Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients

  • Kim, Dae Cheol (Department of Pathology, Dong-A University College of Medicine) ;
  • Kim, Ki Uk (Departments of Neurosurgery, Dong-A University College of Medicine) ;
  • Kim, Young Zoon (Division of Neurooncology, Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine)
  • Received : 2015.08.02
  • Accepted : 2015.10.28
  • Published : 2016.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : This study investigated whether pyrosequencing can be used to determine the methylation status of the MGMT promoter as a clinical biomarker using relatively old archival tissue samples of glioblastoma. We also examined other prognostic factors for survival of glioblastoma patients. Methods : The available study set included formalin-fixed paraffin-embedded (FFPE) tissue from 104 patients at two institutes from 1997 to 2012, all of which were diagnosed histopathologically as glioblastoma. Clinicopathologic data were collected by review of medical records. For pyrosequencing analysis, the PyroMark Q96 CpG MGMT kit (Qiagen, Hilden, Germany) was used to detect the level of methylation at exon 1 positions 17-39 of the MGMT gene, which contains 5 CpGs. Results : Methylation of the MGMT promoter was detected in 43 (41.3%) of 104 samples. The average percentage methylation was $14.0{\pm}16.8%$ overall and $39.0{\pm}14.7%$ for methylated cases. There was no significant pattern of linear increase or decrease according to the age of the FFPE block (p=0.687). In multivariate analysis, age, performance status, extent of surgery, method of adjuvant therapy, and methylation status estimated by pyrosequencing were independently associated with overall survival. Additionally, patients with a high level of methylation survived longer than those with low methylation (p=0.016). Conclusion : In this study, the status and extent of methylation of the MGMT promoter analyzed by pyrosequencing were associated with overall survival in glioblastoma patients. Pyrosequencing is a quantitative method that overcomes the problems of MSP and a simple technique for accurate analysis of DNA sequences.

Keywords

References

  1. Derks S, Lentjes MH, Hellebrekers DM, de Bruïne AP, Herman JG, van Engeland M : Methylation-specific PCR unraveled. Cell Oncol 26 : 291-299, 2004
  2. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. : Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101 : 124-131, 2009 https://doi.org/10.1038/sj.bjc.6605127
  3. Eng J : Receiver operating characteristic analysis : a primer. Acad Radiol 12 : 909-916, 2005 https://doi.org/10.1016/j.acra.2005.04.005
  4. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. : Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 : 1350-1354, 2000 https://doi.org/10.1056/NEJM200011093431901
  5. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, et al. : DNA methylation in glioblastoma : impact on gene expression and clinical outcome. BMC Genomics 11 : 701, 2010 https://doi.org/10.1186/1471-2164-11-701
  6. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. : A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89 : 1827-1831, 1992 https://doi.org/10.1073/pnas.89.5.1827
  7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005 https://doi.org/10.1056/NEJMoa043331
  8. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB : Methylation-specific PCR : a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 : 9821-9826, 1996 https://doi.org/10.1073/pnas.93.18.9821
  9. Jung KW, Ha J, Lee SH, Won YJ, Yoo H : An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain Tumor Res Treat 1 : 16-23, 2013 https://doi.org/10.14791/btrt.2013.1.1.16
  10. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, et al. : Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97 : 311-322, 2010 https://doi.org/10.1007/s11060-009-0031-1
  11. Lantos PL, Louis DN, Rosenblum Mk, Kleihues P : Tumors of the Nervous System. London : Oxford University Press, 2002.
  12. Lee SH, Hwang TS, Koh YC, Kim WY, Han HS, Kim WS, et al. : A consideration of MGMT gene promotor methylation analysis for glioblastoma using methylation-specific polymerase chain reaction and pyrosequencing. Korean J Pathol 45 : 21-29, 2011 https://doi.org/10.4132/KoreanJPathol.2011.45.1.21
  13. Marsh S : Pyrosequencing applications. Methods Mol Biol 373 : 15-24, 2007
  14. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, et al. : Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9 : 368-381, 2007 https://doi.org/10.2353/jmoldx.2007.060167
  15. Park JW, Hwang JH : The long-term survival in patients with anaplastic astrocytoma or glioblastoma. J Korean Neurosurg Soc 34 : 514-520, 2003
  16. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. : Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60 : 5954-5958, 2000
  17. Provenzale JM, Ison C, Delong D : Bidimensional measurements in brain tumors : assessment of interobserver variability. AJR Am J Roentgenol 193 : W515-W522, 2009 https://doi.org/10.2214/AJR.09.2615
  18. Singer-Sam J, Grant M, LeBon JM, Okuyama K, Chapman V, Monk M, et al. : Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 CpG island of mouse embryos at the time of X-chromosome inactivation. Mol Cell Biol 10 : 4987-4989, 1990 https://doi.org/10.1128/MCB.10.9.4987
  19. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 : 459-466, 2009 https://doi.org/10.1016/S1470-2045(09)70025-7
  20. Verbeek B, Southgate TD, Gilham DE, Margison GP : O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85 : 17-33, 2008 https://doi.org/10.1093/bmb/ldm036
  21. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, et al. : Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10 : 332-337, 2008 https://doi.org/10.2353/jmoldx.2008.070169
  22. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW : Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17 : 5612-5619, 1997 https://doi.org/10.1128/MCB.17.9.5612

Cited by

  1. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis vol.14, pp.None, 2016, https://doi.org/10.1186/s12957-016-1012-4
  2. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT vol.126, pp.5, 2016, https://doi.org/10.3171/2016.4.jns1652
  3. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT vol.126, pp.5, 2016, https://doi.org/10.3171/2016.4.jns1652
  4. DNA methylation/hydroxymethylation in melanoma vol.8, pp.44, 2016, https://doi.org/10.18632/oncotarget.18293
  5. Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival vol.78, pp.7, 2019, https://doi.org/10.1093/jnen/nlz032
  6. Investigating DNA Methylation of SHATI/NAT8L Promoter Sites in Blood of Unmedicated Patients with Major Depressive Disorder vol.43, pp.7, 2020, https://doi.org/10.1248/bpb.b19-01099
  7. Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study vol.3, pp.1, 2016, https://doi.org/10.1093/noajnl/vdab171
  8. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review vol.23, pp.9, 2021, https://doi.org/10.1093/neuonc/noab105
  9. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma vol.10, pp.3, 2016, https://doi.org/10.2217/cns-2021-0002